NEW YORK (GenomeWeb) – Investment bank UBS has initiated coverage of the genomics and molecular diagnostics space, saying technology advances will enable "the next wave of transformative innovations that will impact nearly every aspect of our lives," while "creating a unique opportunity for investors." 

Analyst Jon Groberg initiated coverage on a total of 16 firms, and gave six companies Buy ratings, nine companies Neutral ratings, and one firm a Sell rating. 

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

In an against-all-odds twist, a researcher studying exceeding rare FOXG1 mutations discovers her daughter has the syndrome.

An effort by Genomics Medicine Ireland is creating a database of diseases based on the genomics of people in Ireland. It now is looking into the possibility of including Scotland in its work.

In recent weeks, the direct-to-consumer genetics firm has rolled out a health hub where customers can share information concerning 18 common health conditions.

In PLOS this week, new genes associated with prostate cancer risk, genetic patterns in M. bovis, and more.